A treatment selection protocol for recurrent ovarian cancer patients: The role of FDG-PET/CT and staging laparoscopy

Oncology

Volumn 75, Issue 3-4, 2008, Pages 152-158

  Fagotti, A ^a   Fanfani, F ^b   Rossitto, C ^b   Lorusso, D ^a   De Gaetano, A M ^a   Giordano, A ^a   Vizzielli, G ^a   Scambia, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

FDG PET CT; Laparoscopy; Ovarian cancer, recurrent

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTESTINE INJURY; LAPAROSCOPY; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LAPAROSCOPY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 52649180066     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000159266     Document Type: Article

References (35)

1. Hauspy J, Covens A: Cytoreductive surgery for recurrent ovarian cancer. Curr Opin Obstet Gynecol 2007;19:15-21.
2. Benedetti Panici P, De Vivo A, Bellati F, Manci N, Perniola G, Basile S, Muzii L, Angioli R: Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 2007;14:1136-1142.
3. Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS: Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2007;106:482-487.
4. Ayan A, Gultekin M, Taskiran C, et al: The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 2006;194:49-56.
5. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106:1933-1939.
6. Harter P, du Bois A: The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol 2005;17:505-514.
7. Pfisterer J, Harter P, Canzler U, et al: The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer 2005;15:195-198.
8. Zang RY, Li ZT, Tang J, et al: Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004;100:1152-1161.
9. Scarabelli C, Gallo A, Carbone A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001;83:504-512.
10. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-153.
11. Gadducci A, Iacconi P, Cosio S, Fannucci A, Cristofani R, Riccardo Genazzani A: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000;79:344-349.
12. Harter P, Du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schroder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Breitbach GP, Tanner B, Sehouli J, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, AGO Ovarian Cancer Study Group: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006;13:1702-1710.
13. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, Montz FJ: A model for predicting surgical outcome in patient with advanced ovarian carcinoma using computed tomography. Cancer 2000;89:1532-1540.
14. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA: The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 2004;101:346-352.
15. Funt SA, Hricak H, Abu-Rustum N, Mazumdar M, Felderman H, Chi DS: Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 2004;182:393-398.
16. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B: Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005;96:301-306.
17. Bristow RE, del Carmen MG, Pannu HK, et al: Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90:519-528.
18. Bristow RE, Giuntoli RL 2nd, Pannu HK, Schulick RD, Fishman EK, Wahl RL: Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005;99:294-300.
19. 18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007;34:480-486.
20. Hauth EA, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, Kimmig R, Forsting M: Evaluation of integrated whole-body PET/ CT in the detection of recurrent ovarian cancer. Eur J Radiol 2005;56:263-268.
21. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER: FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005;97:183-191.
22. Murakami M, Miyamoto T, Tsukada H, Watanabe M, Shida M, Maeda H, Nasu S, Yasuda S, Yasuda M, Ide M: Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16S:99-107.
23. Nanni C, Rubello D, Farsad M, De Iaco P, Sansovini M, Erba P, Rampin L, Mariani G, Fanti S: F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Cancer Surg 2005;31:792-797.
24. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ: The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006;103:271-276.
25. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 2005;10:177-181.
26. Thrall MM, DeLoia JA, Gallion H, Avril N: Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007;105:17-22.
27. Rose PG, Faulhaber P, Miraldi F, et al: Positron emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:117-121.
28. Fagotti A, Fanfani F, Ludovisi M, Lo Voi R, Bifulco G, Testa AC, Scambia G: Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer patients: a pilot study. Gynecol Oncol 2005;96:729-735.
29. Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, Scambia G: A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006;13:1156-1161.
30. Angioli R, Palaia I, Zullo MA, Muzii L, Manci N, Calcagno M, Benedetti Panici P: Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol 2006;100:455-461.
31. Deffieux X, Castaigne D, Pomel C: Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 2006;16(suppl 1):35-40.
32. Testa AC, Fruscella E, Ludovisi M, De Vincenzo R, Malaggese M, Corrado G, Basso D, Scambia G, Ferrandina G: The role of sonographic examination in the follow-up of gynaecological neoplasm. Gynecol Oncol 2005;99:696-703.
33. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G: Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer 2006;42:2296-2302.
34. Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, Scambia G: Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 2003;65:316-322.
35. Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, Bristow RE: Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007;109:685-691.